Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.56 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 2/20 | 0.55 |
| ▸ | CDC25A | P30304 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285932 | 0.97 | TDP1 (0.69) | TDP1L3MBTL1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL6283360 | 0.95 | TDP1 (0.71) | TDP1L3MBTL1MEN1KMT2ACES1 | |
| SCHEMBL6283135 | 0.92 | TDP1 (0.66) | TDP1L3MBTL1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL29418113 | 0.90 | ALDH1A1 (0.67) | TDP1L3MBTL1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL45324 | 0.90 | ALDH1A1 (0.67) | TDP1L3MBTL1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL9220253 | 0.89 | TDP1 (0.76) | TDP1L3MBTL1MAOBCYP1B1 | |
| SCHEMBL23731163 | 0.88 | CES1 (0.68) | TDP1L3MBTL1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL732925 | 0.88 | CES1 (0.68) | TDP1L3MBTL1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL8862943 | 0.88 | CES1 (0.68) | TDP1L3MBTL1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL10725536 | 0.88 | CES1 (0.68) | TDP1L3MBTL1ALDH1A1ALDH2ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163758-B2 | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity | PARION SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | CACNA1C, CACNA1B, CACNA1G | TDP1 4087/4885L3MBTL1 3988/4885ALDH1A1 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.